<SEC-DOCUMENT>0001708599-25-000042.txt : 20250414
<SEC-HEADER>0001708599-25-000042.hdr.sgml : 20250414
<ACCEPTANCE-DATETIME>20250414162804
ACCESSION NUMBER:		0001708599-25-000042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250408
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250414
DATE AS OF CHANGE:		20250414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Serina Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001708599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				821436829
		STATE OF INCORPORATION:			AL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38519
		FILM NUMBER:		25836346

	BUSINESS ADDRESS:	
		STREET 1:		601 GENOME WAY
		STREET 2:		SUITE 2001
		CITY:			HUNTSVILLE
		STATE:			AL
		ZIP:			35806
		BUSINESS PHONE:		(256) 327-9630

	MAIL ADDRESS:	
		STREET 1:		601 GENOME WAY
		STREET 2:		SUITE 2001
		CITY:			HUNTSVILLE
		STATE:			AL
		ZIP:			35806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgeX Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ser-20250408.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a78f25fb-8dc0-4dbd-aec5-05fcf8d2695d,g:c7ac0398-a3ef-4edb-844d-88c3c0c91da0,d:fb7f44aeeb9f4960bb43eff7421ae122-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ser-20250408</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001708599</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-24">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ser-20250408.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001708599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-08</xbrli:startDate><xbrli:endDate>2025-04-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April&#160;8, 2025</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Serina Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-38519</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">82-1436829</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">601 Genome Way</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 2001</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Huntsville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">35806</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">(256)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">327-9630</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">SE</ix:nonNumeric>R</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NYSE American</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_86"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Entry into a Material Definitive Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 8, 2025, Serina Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain investors (collectively, the "Investors") for a private placement of securities (the "Private Placement"). At the closing of the Private Placement, the Company will issue an aggregate of 962,250 shares of the Company's Series A Convertible Preferred Stock, par value $0.0001 (the "Series A Preferred Stock"), at a purchase price of $5.18 per share of Series A Preferred Stock. The Company has received aggregate gross proceeds from the Private Placement of approximately $5 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each share of Series A Preferred Stock is convertible into shares of the Company's common stock, par value ($0.0001 (the "Common Stock"), at a conversion price of $5.18 per share. The shares of Series A Preferred Stock shall be issued to the Investors, and any shares of Common Stock issuable upon conversion of the Series A Preferred Stock will be issued, pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506(b) of Regulation D as promulgated by the Securities and Exchange Commission (the "SEC") under the Securities Act. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description is a summary and is qualified in its entirety by reference to the Securities Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_95"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 3.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Unregistered Sales of Equity Securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The disclosures set forth in Item 1.01 above are incorporated by reference into this item 3.02.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_102"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 3.03.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Material Modification to Rights of Security Holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The disclosures set forth in Item 1.01 above and Item 5.03 below are incorporated by reference into this item 3.03.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_110"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.03.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 10, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate of Designations") with the Secretary of State of the State of Delaware, which  became effective upon filing. A description of the material terms of the Series A Preferred Stock is below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ranking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. With respect to (i) payment of dividends, (ii) distribution of assets and (iii) all other liquidation, winding up, dissolution, dividend and redemption rights, the Series A Preferred Stock shall rank </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">pari pass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">u in priority of payment to all Parity Stock (defined below) and senior in priority of payment to all Junior Stock (defined below) in any liquidation, dissolution, winding up or distribution of the Company, and junior to any indebtedness of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Junior Stock&#8221; means (i) the Common Stock and (ii) any other equity interest of the Company, in each case which by its terms ranks junior to the Series A Preferred Stock with respect to payment of dividends and/or distribution of assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Parity Stock&#8221; means any equity interest of the Company hereinafter created which by its terms ranks </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> with the Series A Preferred Stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Series A Preferred Stock carries an annual 8.0% cumulative dividend, which will be paid prior to and in preference over any Junior Stock or Parity Stock.  On March 31st of each year (or if March 31st of such year is not a business day, the first business day following such date) such dividends will be made as a payment in kind.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Voting Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Per each whole share of Series A Preferred Stock, the holders of Series A Preferred Stock will be entitled to cast the number of votes equal to the number of shares of Common Stock into which such holder's Series A Preferred Stock would be convertible into on the record date for the vote or consent of stockholders. The holders of Series A Preferred Stock will vote with the holders of the Common Stock as a single class and on an as-converted basis, except as provided by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mandatory Conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. All shares of Series A Preferred Stock will automatically convert into shares of Common Stock if (i) the volume weighted average price per share of Common Stock is greater than two times the then effective conversion price for ten trading days within any twenty consecutive trading days and (ii) upon the Company completing an underwritten offering or private placement of Common Stock resulting in gross cash proceeds to the Company of at least $20 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Optional Conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Holders of Series A Preferred Stock may convert all of their respective shares of Series C Preferred Stock into shares of Common Stock at any time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Conversion Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The number of shares of Common Stock that each holder of Series A Preferred Stock will receive upon conversion of such holder&#8217;s shares of Series A Preferred Stock will be equal to the sum of (i) the quotient of the Stated Value of the shares of Series A Preferred Stock to be converted, which is $5.18 per share divided by the Conversion Price, which is initially $5.18 and (ii) any dividends accrued, but not yet issued, with respect to such shares of Series A Preferred Stock being converted. No fractional shares of Common Stock shall be issued upon the exercise of any conversion right. Any fractional shares of Common Stock that a holder would otherwise be entitled to will be rounded up to the next whole share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Holders of Series A Preferred Stock will have rights to certain adjustments for stock dividends stock splits and rights in connection with certain subsequent rights offerings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Series A Preferred Stock does not purport to be complete and is subject to and qualified in its entirety by reference to the form of Series A Preferred Stock Certificate of Designations, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_10"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulation FD Disclosure</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 8, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that, the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.</span></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_13"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 - Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex31_certificateofdesignat.htm">Certificate of Designations</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex31_certificateofdesignat.htm">, dated A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex31_certificateofdesignat.htm">pril </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex31_certificateofdesignat.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex31_certificateofdesignat.htm">, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex101_pipesecuritiespurcha.htm">Securities Purchase Agreement,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex101_pipesecuritiespurcha.htm"> dated A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex101_pipesecuritiespurcha.htm">p</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex101_pipesecuritiespurcha.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex101_pipesecuritiespurcha.htm">il 8, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250408xex991pronpipe.htm">Press Release, dated </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250408xex991pronpipe.htm">April </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250408xex991pronpipe.htm">8</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250408xex991pronpipe.htm">, 2025, issued by Serina Therapeutics, Inc</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (embedded within the Inline XBRL document) </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifb7f44aeeb9f4960bb43eff7421ae122_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">SERINA THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: April&#160;14, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">/s/ Steve Ledger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex31_certificateofdesignat.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_1"></div><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:96.25pt;padding-right:96.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS</font></div><div style="margin-top:0.05pt;padding-left:96.3pt;padding-right:96.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt">OF</font></div><div style="padding-left:130.6pt;padding-right:130.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SERIES A CONVERTIBLE PREFERRED STOCK OF</font></div><div style="padding-left:96.27pt;padding-right:96.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SERINA THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to Section 151 of the Delaware General Corporation Law (as amended, supplemented or restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Serina Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in accordance with the provisions of Section 103 of the DGCL, DOES HEREBY CERTIFY&#58;</font></div><div style="margin-top:12.6pt;padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">That the First Amended and Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), currently authorizes the issuance of up to Five Million (5,000,000) shares of preferred stock, par value $0.0001 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">That, pursuant to the Certificate of Incorporation, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is authorized to fix by resolution or resolutions the designation and number of the shares of a series of Preferred Stock and the powers, preferences and rights of such series, and the qualifications, limitations or restrictions thereof.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">That, pursuant to the authority conferred upon the Board by the Certificate of Incorporation, the Board adopted the following resolution designating a new series of Preferred Stock as &#8220;Series A Convertible Preferred Stock&#8221;&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RESOLVED, that, pursuant to the authority vested in the Board in accordance with the provisions of Section 4.2 of the Certificate of Incorporation and the provisions of Section 151 of the DGCL, a series of Preferred Stock of the Company is hereby authorized, and the number of the shares of such series and the powers, preferences and rights of such series, and the qualifications, limitations or restrictions of such series, shall be as follows&#58;</font></div><div style="margin-top:12.6pt;padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Designation and Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The shares of such series of Preferred Stock shall be designated as &#8220;Series A Convertible Preferred Stock&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The number of authorized shares constituting the Series A Preferred Stock shall be 965,250. That number may from time to time be increased (but not above the total number of authorized shares of Preferred Stock) or decreased (but not below the number of shares of Series A Preferred Stock then outstanding) by further resolution duly adopted by the Board, or any duly authorized committee thereof, and by the filing of a certificate pursuant to the provisions of the DGCL stating that such increase or decrease, as applicable, has been so authorized. Unless otherwise determined by the Company, all shares of Series A Preferred Stock issued will be delivered on a book- entry basis. The Company shall have the authority to issue fractional shares of Series A Preferred Stock.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Ranking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Series A Preferred Stock shall rank senior to all of the Common Stock and any other capital stock of the Company with respect to the preferences as to dividends, distributions and payments upon a Liquidation Event&#59; however, the Series A Preferred Stock shall be of junior rank to any indebtedness by the Company, excluding equity securities and non-convertible preferred stock. The rights of the shares of Common Stock shall be of junior rank to and subject to the preferences and relative rights of the Series A Preferred Stock. Subject to the terms of the Series A Preferred Stock, the Company shall be permitted to issue capital stock, including Preferred Stock, that is junior in rank to the Series A Preferred Stock in respect of the rights, preferences, or privileges, including without limitation the preferences as to dividends and other</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_4"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">distributions, as to redemption payments, and as to payments upon a Liquidation Event (such stock being referred to hereinafter collectively as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Junior Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of a Liquidation Event, holders of Series A Preferred Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be entitled to receive in cash out of the assets of the Company legally available therefor, whether from capital or from earnings available for distribution to its stockholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidation Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) upon such Liquidation Event, but before any amount shall be paid to the holders of Junior Stock, an amount in cash per share of Series A Preferred Stock equal to the greater of&#58; (i) the Stated Value and</font></div><div style="padding-left:5pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) the value of the per share consideration paid to the holders of the Common Stock in the Liquidation Event as if the Series A Preferred Stock held by such Holder had been converted prior to the Liquidation Event&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if the Liquidation Funds are insufficient to pay the full amount due to the Holders and holders of shares of other classes or series of preferred stock of the Company, if any, that are of equal rank with the Series A Preferred Stock as to payments of Liquidation Funds (such stock being referred to hereinafter collectively as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parity Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), if any, then the Holders and the holders of any such Parity Stock shall share ratably in any distribution of the Liquidation Funds in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to the shares of Series A Preferred Stock and Parity Stock were paid in full. In addition, to the extent any Liquidation Funds remain following payment of the liquidation preference on the Series A Preferred Stock and any other payments that rank senior to payments on the Common Stock, each Holder shall be entitled to its pro rata portion of the remaining Liquidation Funds payable to the holders of the Common Stock in respect of any accrued but unpaid dividends on the Series A Preferred Stock as if any such accrued but unpaid dividends had been paid out in Common Stock immediately prior to the Liquidation Event.</font></div><div><font><br></font></div><div style="padding-left:75.55pt;text-indent:-34.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.3pt;text-decoration:underline">Dividends.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">Beginning on March 31, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initial Dividend Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and annually on March 31st of each year thereafter (or, if such day is not a Business Day, on the first Business Day following such date) (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) the Company shall pay to the Holders of record as they appear on the books of the Company on such Dividend Payment Date of such year (even if such day is not a Business Day) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; dividends per share of Series A Preferred Stock held on the applicable Dividend Record Date in arrears for the prior twelve-month period (except for the Dividend to be paid on the Initial Dividend Date, which shall be paid in arrears for the period from the Initial Closing Date through the Initial Dividend Date), payable in the form of the number of shares of Common Stock (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PIK Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) equal to the Stated Value of each such share of Series A Preferred Stock </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Dividend Rate and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">divided by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> $5.18 as adjusted from time to time to give effect to Section 9(e) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which shall accrue in four (4) equal quarterly installments on the first day of each Calendar Quarter beginning on April 1, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">The Dividends will be satisfied solely by delivery of shares of Common Stock. No fractional shares of Common Stock are to be issued upon the payment of Dividends, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number. To the extent not previously paid, Dividends shall be accelerated and paid in connection with the consummation of a conversion, redemption or Fundamental Transaction with respect to all shares of Series A Preferred Stock subject to such conversion, redemption or Fundamental Transaction.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">Notwithstanding the foregoing, to the extent that the issuance by the Company of PIK Shares pursuant to any Holder&#8217;s right to participate in a Dividend would result in the Company exceeding the Exchange Cap prior to the receipt of Stockholder Approval (as defined below), then such Holder shall</font></div><div><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.611%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></td></tr></table></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_7"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41pt;padding-right:8.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not be entitled to participate in any such Dividend to such extent (or in the beneficial ownership of any PIK Shares as a result of such dividend to such extent) and the portion of such PIK Shares that would cause the Company to exceed the Exchange Cap shall be held by the Company in abeyance for the benefit of such Holder (which shall not give the Holder any power to vote or dispose of such PIK Shares) until such time, if ever, as such Holder&#8217;s beneficial ownership thereof would not result in such Holder exceeding the Exchange Cap.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">To the extent any required Dividends are not paid on the applicable Dividend Date, the amount of any such unpaid Dividends shall be deemed to have accrued over the applicable twelve-month period (except for the Dividend to be paid on the Initial Dividend Date, which shall be paid in arrears for the period from the Initial Closing Date through the Initial Dividend Date). Such accrual of Dividends shall be cumulative and shall continue to accrue whether or not declared and whether or not in any relevant period there shall be net profits or surplus available for the payment of Dividends in such period, so that if in any period or periods, Dividends in whole or in part are not paid upon the Series A Preferred Stock for any reason, unpaid Dividends shall accumulate thereon on each applicable Dividend Date for which Dividends are not paid up to but excluding the day on which the Company delivers payment for all Dividends that are then in arrears or until the conversion or redemption of the applicable shares of Series A Preferred Stock or a Fundamental Transaction.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Holder&#8217;s Conversion Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Holder shall have the right, at such Holder&#8217;s option, subject to the conversion procedures set forth in Section 7 and the limitation on conversion set forth in Section 8, to convert any or all of its shares of Series A Preferred Stock at any time into the number of fully paid, validly issued and nonassessable shares of Common Stock equal to the sum of (i) the quotient of the Stated Value of the shares of Series A Preferred Stock to be converted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">divided by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Conversion Price (as defined below) and (ii) any PIK Shares accrued, but not yet issued, with respect to such shares of Series A Preferred Stock being converted. No fractional shares of Common Stock are to be issued upon the conversion of any Series A Preferred Stock, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall initially be $5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and from time to time in effect shall be subject to adjustment as hereinafter provided.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:75.55pt;text-indent:-34.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.3pt;text-decoration:underline">Mandatory Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">All issued and outstanding shares of Series A Preferred Stock will automatically convert into shares of Common Stock as follows&#58; (i) if, at any time after the applicable Issuance Date, the VWAP per share of the Company&#8217;s Common Stock is greater than two times (2x) the then-effective Conversion Price per share for at least ten (10) Trading Days in any period of twenty (20) consecutive Trading Days (such twenty (20) consecutive Trading Day period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trading Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or (ii) if the Company completes an underwritten offering or private placement of the Company&#8217;s Common Stock resulting in gross cash proceeds, prior to the payment of underwriting discounts or other fees and expenses of the offering, of at least Twenty Million Dollars ($20,000,000) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Qualified Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in which the price per share of Common Stock equal to or greater than the then-effective Conversion Price.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt;text-decoration:underline">Notice of Mandatory Conversion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company shall, within ten (10) Business Days following the completion of the applicable Trading Period referred to in Section 6(a) above, provide notice of the Mandatory Conversion to each Holder (such notice, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notice of Mandatory Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). For the avoidance of doubt, a Notice of Mandatory Conversion does not limit a Holder&#8217;s right to convert on a Conversion Date prior to the Mandatory Conversion Date (as defined below). The Company shall select a date for the conversion of any shares of Series A Preferred Stock pursuant to this Section 6, which </font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41pt;padding-right:7.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date shall be no less than ten (10) Business Days and no more than twenty (20) Business Days after the date on which the Company provides the Notice of Mandatory Conversion to the Holders (the</font></div><div style="height:95.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.611%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></td></tr></table></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_10"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Mandatory Conversion Date&#8221;). The Notice of Mandatory Conversion shall state, as appropriate&#58; (i) the Mandatory Conversion Date selected by the Company&#59; and (ii) the Conversion Price as expected to be in effect on the Mandatory Conversion Date, the number of shares Series A Preferred Stock to be converted from such Holder and the number of shares of Common Stock to be issued to such Holder upon conversion of each such share of Series A Preferred Stock, plus the amount of any shares of Common Stock to be issued in respect of accrued and unpaid Dividends.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">Promptly following the Mandatory Conversion Date, the Company shall deliver to each Holder notices of uncertificated shares free of restrictive legends representing (i) the shares of Common Stock issuable upon conversion of such Holder&#8217;s Series A Preferred Stock pursuant to Section 6(a)&#59; and</font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) any PIK Shares issuable to such Holder upon Mandatory Conversion pursuant to Section 4(b) as of the Mandatory Conversion Date.</font></div><div style="margin-top:12.6pt;padding-left:41pt;padding-right:7.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">If a Mandatory Conversion consummated in full would violate the limitation on conversion set forth in Section 8, such Holder shall continue to be a holder of Series A Preferred Stock entitled to all the rights of a holder of Series A Preferred Stock with respect to such Series A Preferred Stock. With respect to any Mandatory Conversion pursuant to this Section 6(d), the Company must simultaneously take the same action in the same proportion with respect to all shares of Series A Preferred Stock, to the extent practicable or, if the pro rata basis is not practicable for any reason, by lot or such other equitable method as the Company determines in good faith. At each Mandatory Conversion Date, each share of Series A Preferred Stock to be converted pursuant to such Mandatory Conversion shall automatically be converted into fully paid, validly issued and nonassessable shares of Common Stock as of the applicable Mandatory Conversion Date without any further act or deed on the part of the Company, any Holder or any other Person.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:75.5pt;text-align:justify;text-indent:-34.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.25pt;text-decoration:underline">Conversion Procedures and Effect of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.75pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt;text-decoration:underline">Mechanics of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The conversion of shares of Series A Preferred Stock to Common Stock shall be conducted in the following manner&#58;</font></div><div><font><br></font></div><div style="padding-left:77pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.63pt">in the case of a conversion pursuant to Section 5, the Holder shall complete and manually sign the conversion notice substantially in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conversion Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and deliver such notice to the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that a Conversion Notice may be conditioned upon the completion of a corporate transaction&#59;</font></div><div><font><br></font></div><div style="padding-left:77pt;padding-right:7.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.58pt">if requested by the Company, the Holder shall furnish appropriate and as required endorsements and transfer documents&#59; and</font></div><div style="margin-top:12.6pt;padding-left:77pt;padding-right:7.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.53pt">if requested by the Company, the Holder shall pay any stock transfer, documentary, stamp or similar taxes not payable by the Company pursuant to Section 7(d).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing clauses (ii) and (iii) shall be conditions to the issuance of shares of Common Stock to the Holders in the event of a Mandatory Conversion pursuant to Section 6 (but, for the avoidance of doubt, failure on the part of the Holder to fulfill such conditions shall not impact the effectiveness of the Mandatory Conversion on the Mandatory Conversion Date).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (A) with respect to conversion of any shares of Series A Preferred Stock at the option of any Holder pursuant to Section 5, the date on which such Holder complies with the procedures in this Section 7(a) (including the satisfaction of any conditions to conversion set forth in the Conversion Notice) and (B) with respect to Mandatory Conversion pursuant to Section 6(a), the Mandatory Conversion Date.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_13"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:7.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with a conversion, any shares of Common Stock issued will, unless otherwise determined by the Company, be delivered to the Holder on a book-entry basis and shall be delivered promptly after the applicable Conversion Date.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.18pt;text-decoration:underline">Effect of Conversion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Effective immediately prior to the close of business on the Conversion Date applicable to any shares of Series A Preferred Stock, Dividends shall no longer be declared or, as applicable, accrue on any such shares of Series A Preferred Stock, and such shares of Series A Preferred Stock shall cease to be outstanding.</font></div><div style="margin-top:12.6pt;padding-left:5pt;padding-right:7.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.8pt;text-decoration:underline">Record Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Person or Persons entitled to receive the shares of Common Stock issuable upon a conversion of shares of Series A Preferred Stock shall be treated for all purposes as the record holder or holders of such shares of Common Stock on the applicable Conversion Date.</font></div><div style="margin-top:12.6pt;padding-left:5pt;padding-right:7.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.18pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. (i) The Company shall pay any and all transfer, stamp and similar taxes owed by it that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Series A Preferred Stock. However, the Company shall not be required to pay any such tax that may be payable in respect of any transfer involved in the issuance or delivery of shares of Series A Preferred Stock, shares of Common Stock or other securities to a beneficial owner other than the beneficial owner of the Series A Preferred Stock immediately prior to such conversion, and shall not be required to make any such issuance, delivery or payment unless and until the Person otherwise entitled to such issuance, delivery or payment has paid to the Company the amount of any such tax or has established, to the satisfaction of the Company, that such tax has been paid or is not payable. (ii) All payments and distributions (or deemed distributions) on the shares of Series A Preferred Stock (and on the shares of Common Stock received upon their conversion) shall be subject to withholding and backup withholding of taxes to the extent required by law, subject to applicable exemptions, and amounts withheld, if any, shall be treated as received by the Holders.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Common Stock Issuance Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any other provision in this Certificate of Designations, the Company shall not be permitted to issue any shares of Common Stock pursuant to the terms of this Certificate of Designations, and the Holders shall not have the right to receive any shares of Common Stock pursuant to the terms of this Certificate of Designations, to the extent the issuance of such shares of Common Stock would exceed the aggregate number of shares of Common Stock that is equal to 19.9% of the amount of Common Stock of the Company outstanding immediately preceding the date of the Securities Purchase Agreement, which is the maximum amount of shares that the Company may issue pursuant to the terms of this Certificate of Designations without breaching the Company&#8217;s obligations under the rules or regulations of the Principal Market (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except that such limitation shall not apply in the event that the Company obtains the approval of its stockholders as provided by the applicable rules of the Principal Market for issuances of Common Stock in excess of such amount (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Furthermore, in the event the Exchange Cap applies, until such Stockholder Approval is obtained, each initial purchaser of the Series A Preferred Stock party to the Securities Purchase Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initial Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) may only convert the shares of Series A Preferred Stock received by the Initial Holder into a number of shares of Common Stock equal to the product of the Exchange Cap multiplied by a fraction, the numerator of which is the number of shares of Series A Preferred Stock issued to such Initial Holder, and the denominator of which is the number of outstanding shares of Series A Preferred Stock, rounded down to the nearest whole share (with respect to each such Holder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Cap Allocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). If any Initial Holder shall sell or otherwise transfer any of such Initial Holder&#8217;s Series A Preferred Stock, the transferee shall be allocated a pro rata portion of such Initial Holder&#8217;s Exchange Cap Allocation with respect to such portion of the Series A Preferred Stock sold or otherwise transferred, and the restrictions of the prior sentence shall apply to such transferee with respect to the portion of the Exchange Cap Allocation allocated to such transferee. Within sixty (60) days of the Exchange Cap applying such that one or more Holders are limited with respect to the number of shares of Common Stock that may be issued pursuant to the terms of this Certificate of Designations, the Company agrees to use commercially reasonable efforts to call a meeting of its stockholders, which meeting shall be held within ninety (90) days of the Initial Closing Date, for the holders of Common Stock to vote on the issuance of shares of Common Stock upon conversion of the Series A Preferred Stock and the Dividends payable in respect thereof in excess of the Exchange Cap in</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_16"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">accordance with applicable law and the rules and regulations of the Principal Market (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stockholder Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.75pt;text-decoration:underline">Adjustments to Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Conversion Price will be subject to adjustment from time to time as provided in this Section 9.</font></div><div style="margin-top:12.65pt;padding-left:41pt;padding-right:7.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt;text-decoration:underline">Adjustment of Conversion Price upon Qualified Offering below Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If, on or after the Initial Closing Date, the Company consummates a Qualified Offering for a consideration per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Qualified Offering Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) less than the Conversion Price in effect immediately prior to such issuance or sale (the foregoing, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dilutive Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then immediately after such Dilutive Issuance, the Conversion Price in effect immediately prior to the Dilutive Issuance shall automatically be reduced to an amount equal to the Qualified Offering Price, and then all issued and outstanding shares of Series A Preferred Stock will automatically convert into shares of Common Stock at the new Conversion Price equal to the Qualified Offering Price, pursuant to the mandatory conversion mechanics in Sections 6(b),</font></div><div style="margin-top:0.05pt;padding-left:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) and (d).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt;text-decoration:underline">Adjustment of Conversion Price upon Subdivision or Combination of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the Company subdivides (by any stock split, stock dividend (other than this issuance of PIK Shares), recapitalization or otherwise) its outstanding shares of Common Stock, or any series thereof, into a greater number of shares, the Conversion Price and the Dividend Price in effect immediately prior to such subdivision will be proportionately reduced. If the Company combines (by combination, reverse stock split or otherwise) its outstanding shares of Common Stock, or any series thereof, into a smaller number of shares, the Conversion Price and the Dividend Price in effect immediately prior to such combination will be proportionately increased. Any adjustment under this Section 9(b) shall become effective at the time that the subdivision or combination becomes effective.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt;text-decoration:underline">Notice of Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Promptly upon any adjustment of the Conversion Price pursuant to this Section 9, the Company shall give written notice thereof to each Holder, setting forth in reasonable detail the calculation of such adjustment.</font></div><div style="margin-top:12.6pt;padding-left:81pt;text-align:justify;text-indent:-40pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.25pt;text-decoration:underline">Reservation of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:7.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt;text-decoration:underline">Reservation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall at all times reserve out of its authorized and unissued shares of Common Stock a number of shares of Common Stock equal to 100% of the maximum number of shares of Common Stock issuable with respect to the then outstanding Series A Preferred Stock, including the payment of PIK Shares (assuming for purposes hereof that (i) the shares of Series A Preferred Stock are convertible at the initial Conversion Price and (ii) dividends on the shares of Series A Preferred Stock are paid in the form of PIK Shares for a period of three years after the Initial Closing Date, and without taking into account any limitations on the conversion of the Series A Preferred Stock set forth herein). So long as any shares of Series A Preferred Stock are outstanding, the Company shall take all action necessary to reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of effecting the conversion of the Series A Preferred Stock, at least the number of shares of Common Stock specified above in this Section 10(a) as shall from time to time be necessary to effect the conversion of all of the Series A Preferred Stock then outstanding, based upon the then- effective Conversion Price (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Required Reserve Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt;text-decoration:underline">Insufficient Authorized Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If at any time while any of the shares of Series A Preferred Stock remain outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon conversion of the Series A Preferred Stock at least a number of shares of Common Stock equal to the Required Reserve Amount (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Authorized Share Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the Company shall use its commercially reasonable efforts to promptly increase the Company&#8217;s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the shares of Series A Preferred Stock</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.466%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></td></tr></table></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_19"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41pt;padding-right:7.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than one year after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its commercially reasonable efforts to solicit its stockholders&#8217; approval of such increase in authorized shares of Common Stock and to cause the Board to recommend to the stockholders that they approve such proposal.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Holder shall be entitled to the whole number of votes equal to the number of shares of Common Stock into which such Holder&#8217;s Series A Preferred Stock would be convertible on the record date for the vote or consent of stockholders at a conversion price of $5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">per share of Common Stock rounded to the nearest whole share (subject to the limitation on conversion set forth in Section 8), and shall otherwise have voting rights and powers equal to the voting rights and powers of the Common Stock to the fullest extent permitted by applicable law, including, for the avoidance of doubt, with respect to the election of the Company&#8217;s directors. Each Holder shall be entitled to receive the same prior notice of any stockholders&#8217; meeting as is provided to the holders of Common Stock in accordance with the bylaws of the Company, as well as prior notice of all stockholder actions to be taken by legally available means in lieu of a meeting, and shall vote as a class with the holders of Common Stock as if they were a single class of securities upon any matter submitted to a vote of stockholders, except those matters required by Section 242 of the DGCL or by the terms hereof to be submitted to a class vote of the Holders, in which case the Holders only shall vote as a separate class. The Series A Preferred Stock, when voting along with the Common Stock, shall be counted for purposes of establishing a quorum.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Equal Treatment of Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No consideration shall be offered or paid to any of the Holders to amend or waive or modify any provision of the Series A Preferred Stock unless the same consideration (other than the reimbursement of legal fees) is also offered to all of the Holders. This provision constitutes a separate right granted to each of the Holders by the Company and shall not in any way be construed as the Holders acting in concert or as a group with respect to the purchase, disposition or voting of securities or otherwise.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:81.05pt;text-indent:-40.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.3pt;text-decoration:underline">Protective Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">At any time when shares of Series A Preferred Stock are outstanding, the Company shall not, and shall not allow any subsidiary to, either directly or indirectly by amendment, merger, consolidation, recapitalization, reclassification, or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the Requisite Holders given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect&#58; (a) amend, alter or change the powers, privileges or preferences of the Series A Preferred Stock, (b) amend, alter or repeal any provision of the Certificate of Incorporation, this Certificate of Designations or bylaws of the Company in a manner that adversely affects the powers, preferences or rights of the Series A Preferred Stock but does not so affect the other shares of capital stock of the Company, or (c) (i) reclassify, alter or amend any existing security of the Company that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pari passu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with or junior to the Series A Preferred Stock, if such reclassification, alteration or amendment would render such other security senior to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pari passu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with, respectively, the Series A Preferred Stock or (ii) reclassify, alter or amend any existing security of the Company that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pari passu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with or junior to the Series A Preferred Stock, if such reclassification, alteration or amendment would render such other security senior to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pari passu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with, respectively, the Series A Preferred Stock.</font></div><div><font><br></font></div><div style="margin-top:9.55pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_22"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">For the avoidance of doubt, the consent rights in Section 13(a) shall not apply with respect to any such actions taken upon (or immediately prior to) a Fundamental Transaction, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the effectiveness of any such action shall be conditioned upon the consummation of such Fundamental Transaction and compliance with the other provisions of this Certificate of Designations applicable in the event of a Fundamental Transaction. Any amendment or waiver to this Certificate of Designations made in conformity with the provisions of this Section 13 shall be binding on all Holders. No such amendment or waiver shall be effective to the extent that it applies to less than all of the Holders. No vote of any class of stock other than the Series A Preferred Stock shall be required to change, amend or waive any provision of the Certificate of Designations with respect to the Series A Preferred Stock except as required by law or by another provision of the Company&#8217;s Certificate of Incorporation.</font></div><div style="margin-top:12.65pt;padding-left:81.05pt;text-indent:-40.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.3pt;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">In addition to the above provisions with respect to Series A Preferred Stock, such Series A Preferred Stock shall be subject to and be entitled to the benefit of the provisions set forth in the Certificate of Incorporation of the Company with respect to preferred stock of the Company generally&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that in the event of any conflict between such provisions, the provisions set forth in this Certificate of Designations shall control.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">Any shares of Series A Preferred Stock that are converted or repurchased in full shall automatically be deemed cancelled.</font></div><div style="margin-top:12.6pt;padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">Whenever notice is required to be given under this Certificate of Designations, unless otherwise provided herein, such notice shall be given in accordance with the Securities Purchase Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">Whenever any payment of cash is to be made by the Company to any Person pursuant to this Certificate of Designations, such payment shall be made in lawful money of the United States of America via wire transfer of immediately available funds to an account designated by such Holder. Whenever any amount expressed to be due by the terms of this Certificate of Designations is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day without interest or penalty.</font></div><div style="margin-top:12.6pt;padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Governing Law&#59; Jurisdiction&#59; Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Certificate of Designations shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Certificate of Designations shall be governed by, the internal laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Delaware.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Series A Preferred Stock Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall maintain at its principal executive offices (or such other office or agency of the Company or its Transfer Agent as the Company may designate by notice to the Holders), a register (which may be in electronic form) for the Series A Preferred Stock, in which the Company shall record the name and address of the persons in whose name the shares of Series A Preferred Stock have been issued, as well as the name and address of each transferee. The Company may treat the person in whose name any share of Series A Preferred Stock is registered on the register as the owner and holder thereof for all purposes, notwithstanding any notice to the contrary, but in all events recognizing any properly made transfers.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Stockholder Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any stockholder approval required, desired or otherwise sought by the Company pursuant to the rules and regulations of the Principal Market, the DGCL, this Certificate of Designations, the Certificate of Incorporation, the bylaws of the Company, or otherwise with respect to the </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.466%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5pt;padding-right:7.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">issuance of the Series A Preferred Stock or the Common Stock issuable upon conversion thereof may be effected at a duly called meeting of the Company&#8217;s stockholders, all in accordance with the applicable rules and</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_25"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">regulations of the Principal Market, the DGCL, this Certificate of Designation, the Certificate of Incorporation, and the bylaws of the Company.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.25pt;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For purposes of this Certificate of Designations the following terms shall have the following meanings&#58;</font></div><div style="margin-top:12.65pt;padding-left:41pt;padding-right:7.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in the City of New York are authorized or required by law to remain closed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in the City of New York are generally are open for use by customers on such day.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of&#58; (i) the period beginning on and including January 1 and ending on and including March 31&#59; (ii) the period beginning on and including April 1 and ending on and including June 30&#59; (iii) the period beginning on and including July 1 and ending on and including September 30&#59; and (iv) the period beginning on and including October 1 and ending on and including December 31.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Securities Purchase Agreement.</font></div><div style="margin-top:12.6pt;padding-left:41pt;padding-right:7.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) the Company&#8217;s shares of common stock, par value $0.0001 per share and (ii) any capital stock into which such Common Stock shall be changed or any capital stock resulting from a reorganization, recapitalization or reclassification of such Common Stock.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:115.55pt;text-indent:-38.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividend Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, 8.0% per annum.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:114.35pt;text-indent:-37.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:7.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any transaction or series of related transactions pursuant to which the Company effects (i) any merger or consolidation of the Company with or into another Person where the Company is not the surviving entity, (ii) any sale of all or substantially all of its assets in one transaction or a series of related transactions, or (iii) any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.</font></div><div style="margin-top:12.5pt;padding-left:41pt;padding-right:7.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initial Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning ascribed to such term in the Securities Purchase Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any share of Series A Preferred Stock, the date of issuance of such share.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidation Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the voluntary or involuntary liquidation, dissolution or winding up of the Company, in a single transaction or series of transactions.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an individual, a limited liability company, a partnership (limited or general), a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:7.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Principal Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the NYSE American Exchange or such other recognized securities exchange on which the Common Stock may be listed.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_28"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:41pt;padding-right:7.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:15.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Requisite Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Holders representing at least a majority of the aggregate shares of Series A Preferred Stock then outstanding.</font></div><div><font><br></font></div><div style="padding-left:116.15pt;text-indent:-39.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.33pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States Securities and Exchange Commission.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:116.15pt;text-indent:-39.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.33pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:7.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain securities purchase agreement, dated on or about the date of filing of this Certificate of Designations, by and among the Company and the Initial Holders pursuant to which the Company will issue the Series A Preferred Stock, as may be amended, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-top:12.5pt;padding-left:41pt;padding-right:7.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:18.23pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Stated Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, per share of Series A Preferred Stock, $5.18 subject to adjustment to preserve such value for stock splits, stock dividends (not including PIK Shares), recapitalizations, reorganizations, reclassifications, combinations, reverse stock splits or other similar events relating to the Series A Preferred Stock.</font></div><div style="margin-top:12.55pt;padding-left:41pt;padding-right:8.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.07pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means one or more Person or Persons formed by, resulting from or surviving any Fundamental Transaction or one or more Person or Persons with which such Fundamental Transaction shall have been entered into.</font></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock on such day, then on the principal securities exchange or securities market on which the Common Stock is then traded.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:7.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Equiniti Trust Company, LLC, or such other agent or agents of the Company as may be designated by the Board as the transfer agent for the Preferred Stock and&#47;or the Common Stock, as applicable.</font></div><div style="margin-top:12.6pt;padding-left:96.27pt;padding-right:96.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* * * * *</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:2.8pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div style="margin-top:7.1pt;padding-left:5pt;padding-right:7.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:134%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%"> The price per share will be inserted prior to release of signature pages equal to the higher of (i) the most recent closing price or (ii) $5.00 per share.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.626%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.55pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></td></tr></table></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_31"></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:5pt;padding-right:23.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Certificate of Designations to be signed as of April 8, 2025.</font></div><div><font><br></font></div><div style="margin-top:1.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:257.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SERINA THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="margin-top:5.3pt"><font><br></font></div><div style="padding-left:254.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.331%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.15pt">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.15pt;text-decoration:underline">&#47;s&#47; Greg Curhan&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:15.47pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.50pt">Name&#58; Curhan</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt;padding-left:15.47pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:11.65pt">Title&#58; Chief Financial Officer</font></div></td></tr></table></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25b5bc12114d4b2dbdf6ca69a1e8bedd_34"></div><hr style="page-break-after:always"><div style="min-height:90.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.6pt"><font><br></font></div><div style="padding-left:96.3pt;padding-right:96.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:96.27pt;padding-right:96.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM OF CONVERSION NOTICE</font></div><div style="margin-top:12.55pt;padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reference is made to the Certificate of Designations, Preferences and Rights (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certificate of Designations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Series A Convertible Preferred Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), of Serina Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In accordance with and pursuant to the Certificate of Designations, the undersigned hereby elects to convert the number of shares of Series A Preferred Stock indicated below into shares of Common Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), of the Company, &#91;as of the date specified below&#93; &#91;upon&#93; &#91;immediately prior to, and subject to the occurrence of, &#91;&#93;&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:0.57pt;padding-right:0.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date of Conversion (if applicable)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12.55pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Number of shares of Series A Preferred Stock to be converted&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tax ID Number (if applicable)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please confirm the following information&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Conversion Price&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Number of shares of Common Stock to be issued&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12.55pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please issue the shares of Common Stock into which the shares of Series A Preferred Stock are being converted in the following name and to the following address&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issue to&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12.55pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Telephone Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authorization&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12.6pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Account Number (if electronic book entry transfer)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:97.5pt;padding-right:97.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Exhibit A to Certificate of Designations&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex101_pipesecuritiespurcha.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8959ca19f1634233aa6e240f88d2a716_1"></div><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-right:25.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTION VERSION</font></div><div style="margin-top:9.5pt"><font><br></font></div><div style="padding-left:94.07pt;padding-right:94.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES PURCHASE AGREEMENT</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement (together with all exhibits and schedules hereto, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is entered into as of April 8, 2025, by and between Serina Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and each of the investors listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Company and the Investors may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; or, collectively, as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:12.6pt;padding-left:94.1pt;padding-right:94.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.81pt">The Company and, as applicable, each Investor will execute and deliver this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or Rule 506(b) of Regulation D (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as promulgated by the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the Securities Act&#59;</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.42pt">The Company has authorized (i) filing a Certificate of Designations, Preferences and Rights, in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), creating a new series of convertible preferred stock of the Company designated as Series A Convertible Preferred Stock, the terms of which are set forth in the Certificate of Designations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), with the holders of the Series A Preferred Stock being entitled to, among other things, receive shares of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as dividends in accordance with the Certificate of Designations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and such Series A Preferred Stock being convertible into Common Stock (as converted, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in accordance with the terms of the Certificate of Designations&#59; and</font></div><div style="padding-left:18.55pt;padding-right:24.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) the issuance and sale to the Investors pursuant to this Agreement of up to 965,250 shares of Series A Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Offered Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), at a price of $5.18 and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:24.6pt;text-align:justify;text-indent:35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.86pt">Each Investor wishes to purchase, and the Company wishes to sell at the applicable Closing (as defined below), upon the terms and conditions stated in this Agreement, the number of shares of Series A Preferred Stock set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> opposite such Investor's name.</font></div><div style="margin-top:12.6pt;padding-left:94.05pt;padding-right:94.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.55pt;padding-right:25.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE, IN CONSIDERATION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the mutual benefits and burdens of the Parties contained in this Agreement and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:94.05pt;padding-right:94.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt">ARTICLE 1</font></div><div style="padding-left:94.1pt;padding-right:94.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt">PURCHASE AND SALE OF SERIES A PREFERRED STOCK</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.3pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the terms and conditions of this Agreement, on the applicable Closing Date (as defined below) the Company shall issue and sell to each Investor, and each Investor severally, and not jointly, shall purchase from the Company, the number of shares of Series A Preferred Stock each as set forth opposite each such Investor&#8217;s name in the Investor Schedule. Each Investor shall pay the Purchase Price (as defined below) for each Offered Share to be purchased by such Investor at the applicable Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Offered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as set forth on the applicable Investor Schedule. The aggregate purchase price for the Series A Preferred Stock shall be the product of (i) $5.18 and (ii) the aggregate number of shares of Series A Preferred Stock purchased by the applicable Investor at the applicable Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8959ca19f1634233aa6e240f88d2a716_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:205.97pt;padding-right:205.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 2 CLOSING</font></div><div style="margin-top:12.65pt;padding-left:54.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.1</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.3pt">The purchase, sale, and issuance of the Offered Shares pursuant to this Agreement shall take place at one or more closings (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, and the applicable date of such closing, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, with the date of the initial closing, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.85pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.68pt">On or before the applicable Closing Date, the Company shall deliver or cause to be delivered to each Investor the following&#58;</font></div><div><font><br></font></div><div style="padding-left:162.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.68pt">this Agreement duly executed by the Company&#59;</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.08pt">an Officer&#8217;s Certificate, dated as of the Initial Closing Date, (i) attaching and certifying on behalf of the Company complete and correct copies of the resolutions authorizing the execution, delivery, and performance by the Company of this Agreement and the transactions contemplated hereby, and (ii) certifying on behalf of the Company the incumbency of each officer of the Company executing this Agreement or any document delivered in connection with the Closing&#59; and</font></div><div style="margin-top:12.6pt;padding-left:162.6pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Company&#8217;s wire instructions.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.65pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.3pt">On or before the applicable Closing Date for each Investor, such Investor shall deliver or cause to be delivered to the Company the following&#58;</font></div><div style="margin-top:12.65pt;padding-left:162.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.68pt">this Agreement duly executed by the Investor&#59; and</font></div><div><font><br></font></div><div style="padding-left:162.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.63pt">the Purchase Price with respect to such Investor, calculated in accordance</font></div><div style="margin-top:0.1pt;padding-left:18.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with Article 1.</font></div><div style="margin-top:12.55pt;padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.68pt">The obligations of the Company to sell and issue the Offered Shares to each Investor on the applicable Closing Date is subject to the fulfillment, to the Company's reasonable satisfaction, on or before the applicable Closing Date, of each of the following conditions&#58;</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.13pt">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) when made and on the applicable Closing Date of the representations and warranties of the Investor contained herein (unless as of a specific date therein in which case they shall be accurate as of such date)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.08pt">all obligations, covenants and agreements of the Investor required to be performed at or prior to the applicable Closing Date shall have been performed&#59; and</font></div><div style="margin-top:12.6pt;padding-left:162.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.58pt">the delivery by the Investor of the items set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this</font></div><div style="margin-top:0.1pt;padding-left:18.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:7.5pt"><font><br></font></div><div style="padding-left:93.97pt;padding-right:93.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.3pt">The obligations of each Investor to purchase the Offered Shares from the Company at the applicable Closing is subject to the fulfillment, to such Investor&#8217;s reasonable satisfaction, on or before the applicable Closing Date, of each of the following conditions&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.13pt">the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) when made and on the applicable Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date)&#59;</font></div><div style="margin-top:12.6pt;padding-left:18.55pt;padding-right:25.95pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.08pt">all obligations, covenants and agreements of the Company required to be performed at or prior to the applicable Closing Date shall have been performed&#59; and</font></div><div><font><br></font></div><div style="padding-left:162.6pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.60pt">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.60pt;padding-left:19.58pt">the delivery by the Company of the items set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.60pt;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.60pt"> of this</font></div><div style="padding-left:18.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:12.60pt">Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On or before April 17, 2025, the Company shall file with the U.S. Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) a Registration Statement on Form S-1 (or, if Form S-3 is then available to the Company, on such form of registration statement as is then available) (either (i) or (ii), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), registering the resale of the Conversion Shares and the number of PIK Shares to be issued for a period of three years after the Initial Closing Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Company shall use commercially reasonable efforts to cause the Registration Statement to become effective within 30 calendar days of filing (or within 60 calendar days of filing in the event of a &#8220;limited review&#8221; by the Commission or within 90 calendar days of filing in the event of a &#8220;full review&#8221; by the Commission) and to keep such registration statement effective at all times any Investor owns any of the Offered Shares or the Shares.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company agrees to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except in the event that the Company consummates&#58; (a) any transaction or series of related transactions as a result of which any Person (together with its Affiliates) acquires securities of the Company representing more than fifty percent (50%) of the voting control of the Company&#59; (b) a merger or reorganization of the Company with one or more other entities in which the Company is not the surviving entity&#59; or (c) a sale of all or substantially all of the assets of the Company, where the consummation of such transaction results in the Company no longer being subject to the reporting requirements of the Exchange Act.</font></div><div style="margin-top:12.6pt"><font><br></font></div><div style="padding-left:94.05pt;padding-right:94.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt;text-decoration:underline">ARTICLE 3</font></div><div style="padding-left:94pt;padding-right:94pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:54.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company hereby represents and warrants to each Investor as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization and Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of Delaware and is in good standing under such laws. The Company has the requisite corporate power and authority to enter into this Agreement, and to sell the Offered Shares and the Shares and carry out and perform its other obligations under the terms of this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All corporate action on the part of the Company and its directors, officers and stockholders necessary for the authorization, execution, delivery and performance of all obligations of the Company under this Agreement and any related Transaction Document (as defined in</font></div><div style="margin-top:6.4pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:93.97pt;padding-right:93.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18.55pt;padding-right:25.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) for the authorization, issuance and delivery of the Offered Shares, and for the authorization, issuance and delivery of the Shares, has been taken. This Agreement and related Transaction Documents constitute the valid and binding obligations of the Company and are enforceable against the Company in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency or other laws affecting the enforcement of creditors&#8217; rights generally, and except that the availability of the remedy of specific performance or other equitable relief is subject to the discretion of the court before which any proceeding therefor may be brought.</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Validity of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as otherwise described in this agreement, the Offered Shares, when issued, sold and delivered in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable, will be free of any liens or encumbrances, and will not be subject to any preemptive rights, rights of first refusal, redemption rights or other restrictions on transfer, other than as provided herein. Assuming the accuracy of the statements made by each Investor in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement, the Offered Shares and the Shares will be issued in compliance with all applicable federal and state securities laws.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.4  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance of this Agreement and the other deliverables, and the consummation of the transactions contemplated hereby and thereby and compliance with the provisions hereof and thereof, by the Company will not (a) violate any provision of law, statute, rule or regulation, or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body applicable to the Company or any of its properties or assets or (b) with due notice or lapse of time, or both, violate, conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default (or give rise to any right of termination, cancellation or acceleration) under, or result in the creation of any encumbrance upon any of the properties or assets of the Company under, its governing documents or any note, indenture, mortgage, lease agreement or other contract, agreement or instrument to which the Company is a party or by which it or any of its properties is bound or affected.</font></div><div style="margin-top:12.6pt;padding-left:18.55pt;padding-right:25.5pt;text-align:justify;text-indent:41.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company has filed or furnished all reports, schedules, forms, certifications, prospectuses, and registration, proxy statements and other documents required to be filed or furnished by it, including all amendments thereto, with the Commission since March 26, 2024 (collectively and together with all documents filed or publicly furnished on a voluntary basis, and in each case including all exhibits and schedules thereto and documents incorporated by reference therein, but excluding any disclosures set forth in any risk factor section, any forward-looking disclosure in any section relating to forward-looking statements or any other statements that are non-specific, cautionary, predictive or forward-looking in nature, other than historical facts included therein, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The SEC Documents, as of their respective effective dates (in the case of the SEC Documents that are Registration Statements filed pursuant to the requirements of the Securities Act) and as of their respective SEC filing dates (in the case of all other SEC Documents), or, if amended, as finally amended, complied in all material respects with the requirements of the Exchange Act, the Securities Act of 1933, as amended, and the Sarbanes-Oxley Act of 2002, as the case may be. There are no outstanding or unresolved comments received from the Commission staff with respect to the SEC Documents. The Company is not aware as of the date of execution of this Agreement of any information that would require the filing of a Current Report on Form 8- K by the Company in the four (4) business days following the date of this Agreement that has not been so filed as of the date of this Agreement (other than any Current Report on Form 8-K that would disclose this Agreement and the transactions related hereto). The SEC Documents do not contain any material misstatements or omissions.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.6  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as expressly contemplated by this Agreement, since the date of the most recent balance sheet of the Company included in the SEC Documents, there has been no event or circumstance that has, or would reasonably be expected to have, individually or in the aggregate,</font></div><div style="margin-top:6.4pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:93.97pt;padding-right:93.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:18.55pt;padding-right:25.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a material adverse effect on the business, financial condition or results of operations of the Company as a whole, excluding any events or circumstances of general application to businesses in the Company&#8217;s industry that do not materially disproportionately impact the Company.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There is no action pending or, to the knowledge of the Company, threatened, in writing against the Company or its Affiliates which, if adversely determined, would prevent the consummation of the transactions contemplated by this Agreement.</font></div><div style="margin-top:12.6pt"><font><br></font></div><div style="padding-left:94.05pt;padding-right:94.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt;text-decoration:underline">ARTICLE 4</font></div><div style="padding-left:94.17pt;padding-right:94.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:12.60pt">REPRESENTATIONS AND WARRANTIES OF EACH INVESTOR</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:54.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Investor, severally and not jointly, hereby represents and warrants to the Company that&#58;</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization and Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If such Investor is an entity, such Investor is in good standing under the laws of its jurisdiction of incorporation or formation, as applicable, and that such Investor has the requisite corporate or entity power and authority to enter into this Agreement, and to purchase the Offered Shares and the Shares and carry out and perform its other obligations under the terms of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Investor has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by such Investor, will constitute valid and legally binding obligations of such Investor, enforceable against such Investor in accordance with their terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors&#8217; rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Entirely for Own Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement is made with such Investor in reliance upon such Investor&#8217;s representation to the Company, which by such Investor&#8217;s execution of this Agreement, such Investor hereby confirms, that the Offered Shares and the Shares to be acquired by such Investor will be acquired for investment for such Investor&#8217;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, such Investor further represents that such Investor does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Offered Shares and the Shares. If such Investor is an entity, such Investor has not been formed for the specific purpose of acquiring the Offered Shares and the Shares.</font></div><div style="margin-top:12.6pt;padding-left:18.55pt;padding-right:25.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.4  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Accredited Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.5  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If such Investor is not a United States person (as defined by Section 7701(a)(30) of the Code), such Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Offered Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Offered Shares and the receipt of the Shares, (ii) any foreign exchange restrictions applicable to such purchase or receipt, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Offered Shares and the Shares. Such Investor&#8217;s subscription and payment for and continued beneficial ownership of the Offered Shares and the Shares will not violate any applicable securities or other laws of such Investor&#8217;s jurisdiction.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.45pt"><font><br></font></div><div style="padding-left:93.97pt;padding-right:93.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8959ca19f1634233aa6e240f88d2a716_7"></div><hr style="page-break-after:always"><div style="min-height:81.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There is no action pending or, to the knowledge of such Investor, threatened, in writing against such Investor or its Affiliates which, if adversely determined, would prevent the consummation of the transactions contemplated by this Agreement.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.7  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sophistication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such Investor (either alone or together with its advisors) has such knowledge and experience in financial or business matters and in investments of this type that it is capable of evaluating the merits and risks of the transaction contemplated by this Agreement. Such Investor has had the opportunity to ask questions and receive answers concerning the terms and conditions of such transaction as it has requested. Such Investor has received all information that it believes is necessary or appropriate in connection with the transaction contemplated by this Agreement. Such Investor acknowledges that it has not relied upon any express or implied representations or warranties of any nature made by or on behalf of the Company, whether or not any such representations, warranties or statements were made in writing or orally, except as expressly set forth for the benefit of such Investor in this Agreement.</font></div><div><font><br></font></div><div style="padding-left:205.97pt;padding-right:205.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> MISCELLANEOUS</font></div><div style="margin-top:12.6pt;padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement shall be governed by and construed under the laws of the State of Delaware.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.2  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The representations, warranties, covenants and agreements made herein shall survive any investigation made by any Investor and the closing of the transactions contemplated hereby.</font></div><div><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.3  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of each Investor.</font></div><div style="margin-top:12.6pt;padding-left:18.55pt;padding-right:25.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement&#59; Amendment&#59; Non-Reliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement among the Parties with regard to the subjects hereof and thereof. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated orally, but only by a written instrument signed by the parties to this Agreement. Each Investor acknowledges and agrees that the neither the Company nor any director, officer, or agent thereof has made or is making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and that such Investor is not relying and has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company acknowledges and agrees that each Investor has not made or is making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and that the Company is not relying and has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:18.55pt;padding-right:25.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.5  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For a notice under this Agreement to be valid, (i) the notice must be in writing and signed by the sending Party, (ii) the sending Party must use one of the following methods of delivery&#58; (A) personal delivery&#59; (B) registered or certified mail, in each case, return receipt requested and postage prepaid&#59; (C) nationally or internationally recognized overnight courier, with all fees prepaid, or</font></div><div style="margin-top:0.05pt;padding-left:18.55pt;padding-right:25.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(D) electronic transmission including electronic mail, and (iii) the notice must be addressed to the receiving Party at the addresses listed below for the receiving Party or to any other address designated by the receiving Party in a notice in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:81.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.4pt"><font><br></font></div><div style="padding-left:93.97pt;padding-right:93.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8959ca19f1634233aa6e240f88d2a716_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:54.55pt;padding-right:23.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to an Investor, addressed to the address set forth beside such Investor&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or at such other address as such Investor shall have furnished to the Company in writing,</font></div><div style="margin-top:12.2pt;padding-left:54.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or if to the Company, addressed as follows&#58;</font></div><div style="margin-top:11.8pt;padding-left:126.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Serina Therapeutics, Inc.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:54.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="margin-top:11.85pt;padding-left:126.55pt;padding-right:213.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bradley Arant Boult Cummings LLP 200 Clinton Avenue West, Suite 900</font></div><div style="padding-left:126.55pt;padding-right:248.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Huntsville, Alabama 35801 Attn&#58; Scott Ludwig</font></div><div style="margin-top:11.5pt;padding-left:18.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">or at such other address as the Company shall have furnished to the Investors and each such other holder in writing.</font></div><div style="margin-top:10.85pt;padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.6  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Finder&#8217;s Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each party represents that it neither is nor will be obligated for any finder&#8217;s fee or commission in connection with this transaction. Each Investor agrees, severally and not jointly, to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which such Investor or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.</font></div><div style="margin-top:10.95pt;padding-left:18.55pt;padding-right:25.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.7  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Construction of Certain Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. Wherever the words &#8220;including,&#8221; &#8220;include&#8221; or &#8220;includes&#8221; are used in this Agreement, they shall be deemed followed by the words &#8220;without limitation.&#8221; References to any gender shall be deemed to mean any gender. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any individual, corporation, partnership, trust, limited liability company, association or other entity, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any Person which, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or similar type position of such Person. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all of the schedules, exhibits, certificates, agreements and other documents contemplated thereby and delivered in connection herewith.</font></div><div style="margin-top:11.05pt;padding-left:18.55pt;padding-right:25.5pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.8  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Delivery of an executed counterpart of a signature page to this Agreement or any Transaction Document by electronic mail or other electronic delivery (including, for the avoidance of doubt, by .PDF, DocuSign, email or other electronic transmission) will be treated in all manner and respects as an original agreement or instrument and will be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.</font></div><div style="margin-top:11pt;padding-left:18.55pt;padding-right:25.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.9  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fees and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each party shall bear its own legal, accounting and other fees and expenses incurred in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated herein.</font></div><div style="margin-top:11.1pt;padding-left:94.07pt;padding-right:94.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;SIGNATURES APPEAR ON FOLLOWING PAGES&#93;</font></div><div><font><br></font></div><div style="margin-top:4.55pt"><font><br></font></div><div style="padding-left:93.97pt;padding-right:93.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:23pt;padding-right:23.6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company has executed this Agreement as of the date first written above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:2.05pt"><font><br></font></div><div style="padding-left:275.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SERINA THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="margin-top:5.75pt"><font><br></font></div><div style="padding-left:275.05pt;padding-right:23.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">&#47;s&#47; Greg Curhan&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> Name&#58; Greg Curhan</font></div><div style="padding-left:275.05pt;padding-right:23.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Its&#58; Chief Financial Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Signature Page to Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.9pt;padding-left:0.77pt;padding-right:0.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INVESTOR SIGNATURE PAGE</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:23pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the undersigned Investor has executed this Agreement as of the date first written above.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:275.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">FOR ENTITIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-top:3.85pt"><font><br></font></div><div style="padding-left:275.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">COMPANY NAME&#58;</font></div><div><font><br></font></div><div style="margin-top:3.65pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:288px"></div><div><font><br></font></div><div style="margin-top:6.45pt"><font><br></font></div><div style="padding-left:275.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:1.85pt;padding-left:275.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="margin-top:1.9pt;padding-left:275.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Its&#58;</font></div><div><font><br></font></div><div style="margin-top:3.8pt"><font><br></font></div><div style="padding-left:275.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">FOR INDIVIDUALS&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.8pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:288px"></div><div style="margin-top:2.55pt;padding-left:31.2pt;padding-right:31.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.45pt"><font><br></font></div><div style="padding-left:1.42pt;padding-right:1.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investor Signature Page to Agreement</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:1.45pt;padding-right:1.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font></div><div style="margin-top:4.1pt"><font><br></font></div><div style="padding-left:1.47pt;padding-right:1.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule of Investors</font></div><div style="margin-top:6.55pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.45pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8959ca19f1634233aa6e240f88d2a716_13"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:1.42pt;padding-right:1.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font></div><div style="margin-top:4.1pt"><font><br></font></div><div style="padding-left:1.42pt;padding-right:1.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Certificate of Designations</font></div><div style="margin-top:4.2pt"><font><br></font></div><div style="padding-left:11.5pt;padding-right:11.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">See attached.</font></div><div style="margin-top:3.9pt;padding-left:94.85pt;padding-right:97.65pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ser-20250408xex991pronpipe.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3067b2f946804c4ab4a61518de659dd0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:justify"><img alt="serina.jpg" src="serina.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:297px"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HUNTSVILLE, April 8, 2025 (GLOBE NEWSWIRE) -- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Serina Therapeutics, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Serina&#8221;) (NYSE American&#58; SER), a clinical-stage biotechnology company developing its proprietary POZ Platform&#8482; drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This financing further strengthens our cash position and reflects the confidence of our strategic investors in the potential of SER-252,&#8221; said Steve Ledger, CEO of Serina Therapeutics. &#8220;With a novel approach to achieving continuous dopaminergic stimulation, we believe SER-252 may offer meaningful clinical benefit to patients with advanced Parkinson&#8217;s disease. We remain focused on initiating first-in-human studies later this year.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the financing, Serina issued 965,250 shares of convertible preferred stock at $5.18 per share, equivalent to the closing price of its common stock on April 7, 2025.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About SER-252 (POZ-apomorphine)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SER 252 is an investigational apomorphine therapy developed with Serina&#8217;s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) and enable greater on time, with reduced off time, in advanced Parkinson&#8217;s patients. SER-252 leverages strategic partner Enable Injections&#8217; enFuse&#8482; wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection without skin reactions. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the POZ Platform&#8482;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serina&#8217;s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina&#8217;s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina&#8217;s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Serina&#8217;s POZ platform delivery technology has potential for use across a broad range of payloads and indications. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Serina Therapeutics</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina&#8217;s POZ Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;serinatherapeutics.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statement</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management&#8217;s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina&#8217;s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data&#59; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities&#59; whether regulatory authorities will be satisfied with the design of and results from our clinical studies&#59; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions&#59; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product&#8217;s benefits outweigh its known risks and determination of the product&#8217;s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful&#59; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of any drug or vaccine candidates&#59; and competitive developments. These risks as well as other risks are more fully discussed in Serina&#8217;s Annual Report on Form 10-K, and Serina&#8217;s other periodic reports and documents filed from time to time with the SEC.  The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For inquiries, please contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stefan Riley </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sriley&#64;serinatherapeutics.com </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(256) 327-9630</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ser-20250408.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a78f25fb-8dc0-4dbd-aec5-05fcf8d2695d,g:c7ac0398-a3ef-4edb-844d-88c3c0c91da0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:SER="http://serinatherapeutics.com/20250408" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://serinatherapeutics.com/20250408">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ser-20250408_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ser-20250408_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://serinatherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ser-20250408_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a78f25fb-8dc0-4dbd-aec5-05fcf8d2695d,g:c7ac0398-a3ef-4edb-844d-88c3c0c91da0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_Security12gTitle_65e19126-dd60-4a8f-9728-ffe9599d6919_terseLabel_en-US" xlink:label="lab_dei_Security12gTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(g) Security</link:label>
    <link:label id="lab_dei_Security12gTitle_label_en-US" xlink:label="lab_dei_Security12gTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(g) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12gTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12gTitle" xlink:to="lab_dei_Security12gTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f19aefa3-9cb4-448a-84cb-f2cbb7c491e7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9b3ec153-e6af-48ac-b3b3-c3c17fb02f0a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_07f8bea6-5198-41ab-befe-12208c185982_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_a80b5995-2e76-442e-8765-345eb68bcdb4_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a5f222d4-9953-4b6e-8b7d-8de2f110c5d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_af62561e-eab4-46d2-bc4e-4f2170b715d4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityBankruptcyProceedingsReportingCurrent_1f33ffe9-d7bd-4f57-8915-3bb6c846a2b5_terseLabel_en-US" xlink:label="lab_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
    <link:label id="lab_dei_EntityBankruptcyProceedingsReportingCurrent_label_en-US" xlink:label="lab_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="lab_dei_EntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_439d5f1a-fae5-44f4-bb42-a35a0c1a3ef9_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0848c6b2-5345-4dee-b398-5985476cda6b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8a7d7d61-784d-4846-802e-caf7ac004e5e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aa762283-0d64-43be-ac76-ec1fc9944511_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5e558df8-d1d6-4bdd-a733-ae9b2e4a1c44_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Extension_12b86cbb-5378-43f7-af84-a8d59a30f21a_terseLabel_en-US" xlink:label="lab_dei_Extension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension</link:label>
    <link:label id="lab_dei_Extension_label_en-US" xlink:label="lab_dei_Extension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Extension" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Extension" xlink:to="lab_dei_Extension" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7a225a0e-2904-4794-8037-18919ab82dab_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_21dc5ba4-324a-4871-938f-2d3acb05fcba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8d01511f-4c7a-4c2f-9f94-3dfb9c60eae8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_14be06a7-51da-4ecd-9771-f2967a32ea32_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentDescription_2a1562e5-fee6-481a-9cf5-9a236eb4b432_terseLabel_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:label id="lab_dei_AmendmentDescription_label_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9b735f26-f6dc-4969-a535-4054370e0f0d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_60fa579a-e091-4713-a57e-22fd3dcaa615_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_62439f76-7db7-4606-90e9-724d5f6c583b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_OtherReportingStandardItemNumber_fbccc078-b4ed-420d-b96b-ee8149630e2c_terseLabel_en-US" xlink:label="lab_dei_OtherReportingStandardItemNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
    <link:label id="lab_dei_OtherReportingStandardItemNumber_label_en-US" xlink:label="lab_dei_OtherReportingStandardItemNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherReportingStandardItemNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_OtherReportingStandardItemNumber" xlink:to="lab_dei_OtherReportingStandardItemNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7f8d0a5b-9db6-4768-a338-ad785458e8f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine3_b9743898-3c29-4e66-9ee9-c3b1a51e99f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d4be64c2-1743-40b9-bf6d-d42b25419327_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9b68dc68-c5db-4059-a90a-12288e0e1821_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_8f0bb7ac-c54b-47ab-8aeb-8a053935033b_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9cb03117-2e24-403d-9f5f-6f4be585484a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e52c54d6-422d-4af1-8222-da589f639c71_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodStartDate_e67f5bd5-0440-44c4-9ce3-025875525867_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodStartDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period Start Date</link:label>
    <link:label id="lab_dei_DocumentPeriodStartDate_label_en-US" xlink:label="lab_dei_DocumentPeriodStartDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period Start Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodStartDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodStartDate" xlink:to="lab_dei_DocumentPeriodStartDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditedAnnualFinancialStatements_6fe0e711-c7f9-4c34-a7dd-f6ed7d4af60d_terseLabel_en-US" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audited Annual Financial Statements</link:label>
    <link:label id="lab_dei_AuditedAnnualFinancialStatements_label_en-US" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audited Annual Financial Statements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditedAnnualFinancialStatements" xlink:to="lab_dei_AuditedAnnualFinancialStatements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6942769f-598d-47e8-af42-17c3c23406d6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_aa966349-b70e-4fc1-bb81-3e9b60291f5e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_be50ec12-18ca-4e8e-958c-fce9d7f4df08_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_330fb45d-d1b7-46c2-895f-e9fc267eb95a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_cb297aef-1b46-4cef-b273-644942483b1d_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_0693df8c-5b7d-4c0a-9468-166e999f03e2_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6dd1970c-576a-42e4-8287-1af0aa381182_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_c99f2ea2-6e01-4b52-a052-ee1177e79710_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b20bbc44-1080-4a64-8cdc-af690052051d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0fe7cc85-6290-416d-b803-f26de9d6f603_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_bbd85dfc-2a9d-4e8d-9c86-89617a914cf5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b4338a29-cb80-45ff-b84d-28d71b35d3c0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPrimarySicNumber_23117d44-3511-40ad-9a3b-7b18b83aef4c_terseLabel_en-US" xlink:label="lab_dei_EntityPrimarySicNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Primary SIC Number</link:label>
    <link:label id="lab_dei_EntityPrimarySicNumber_label_en-US" xlink:label="lab_dei_EntityPrimarySicNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Primary SIC Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d8b0c5dd-7ee8-4865-a7f1-92fac70e4864_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_afc0cb2e-a4c1-4e8c-b496-b243de97ee90_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a2478db7-962c-4090-8d99-0e1baeed8675_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyEventDate_1e4b80ab-c3ab-42fe-afb1-419ae9b905f3_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyEventDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Event Date</link:label>
    <link:label id="lab_dei_DocumentShellCompanyEventDate_label_en-US" xlink:label="lab_dei_DocumentShellCompanyEventDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Event Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyEventDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyEventDate" xlink:to="lab_dei_DocumentShellCompanyEventDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3ef35a4c-0642-4993-9f7d-c57e2821715b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_25b03514-e2e0-4a58-a267-795e10399b64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8f5d2766-cb8e-40da-9bfa-ea59c5332eaa_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cfb261b6-acc8-41f4-8411-b5c2239691bc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_c64b0291-d7e0-4f8c-b6f7-be92f1ce3a24_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2d966854-93cf-44bf-a35d-4e4e73149aeb_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_36669ea8-7a71-4c8a-84fe-557813002189_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityReportingObligation_2c4ca99f-93fa-4eb5-985d-6144f22f647c_terseLabel_en-US" xlink:label="lab_dei_SecurityReportingObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Reporting Obligation</link:label>
    <link:label id="lab_dei_SecurityReportingObligation_label_en-US" xlink:label="lab_dei_SecurityReportingObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Reporting Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityReportingObligation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityReportingObligation" xlink:to="lab_dei_SecurityReportingObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_36369970-06a0-4f39-9004-bdc5cf7b8ab0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AnnualInformationForm_7f52261d-4f10-4014-9f36-bdb1ace04a26_terseLabel_en-US" xlink:label="lab_dei_AnnualInformationForm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Information Form</link:label>
    <link:label id="lab_dei_AnnualInformationForm_label_en-US" xlink:label="lab_dei_AnnualInformationForm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Information Form</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AnnualInformationForm" xlink:to="lab_dei_AnnualInformationForm" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ser-20250408_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a78f25fb-8dc0-4dbd-aec5-05fcf8d2695d,g:c7ac0398-a3ef-4edb-844d-88c3c0c91da0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serinatherapeutics.com/role/Cover" xlink:type="simple" xlink:href="ser-20250408.xsd#Cover"/>
  <link:presentationLink xlink:role="http://serinatherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fe44b7ab-f8b0-43a9-9196-a92b55145d67" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentType_fe44b7ab-f8b0-43a9-9196-a92b55145d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_282a4d5b-9c03-4809-a53c-39113e6d85d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_AmendmentFlag_282a4d5b-9c03-4809-a53c-39113e6d85d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription_d83c5272-b377-4345-ab09-68c3198bd9ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_AmendmentDescription_d83c5272-b377-4345-ab09-68c3198bd9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_74bf4d9e-ea96-443e-a7e9-d00af2ada5d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentRegistrationStatement_74bf4d9e-ea96-443e-a7e9-d00af2ada5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f0a80c1f-8e56-4734-913b-60da38d4b83f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentAnnualReport_f0a80c1f-8e56-4734-913b-60da38d4b83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b454e96e-e8b3-4895-a370-621909413d6a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentQuarterlyReport_b454e96e-e8b3-4895-a370-621909413d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1c09d5b4-4cdf-40bd-9c5a-639bf5f88965" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentTransitionReport_1c09d5b4-4cdf-40bd-9c5a-639bf5f88965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_5a415604-cba4-4ea1-9f46-2ee008025e27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentShellCompanyReport_5a415604-cba4-4ea1-9f46-2ee008025e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyEventDate_91444969-7d5a-48d7-a215-4d8e0a43e398" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentShellCompanyEventDate_91444969-7d5a-48d7-a215-4d8e0a43e398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodStartDate_fdbb9bb3-aeb3-41d6-8729-6a9b92a4df9a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentPeriodStartDate_fdbb9bb3-aeb3-41d6-8729-6a9b92a4df9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ac612ab3-3cf6-41bd-bc70-72f4ff0bd012" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentPeriodEndDate_ac612ab3-3cf6-41bd-bc70-72f4ff0bd012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cf19b91e-c408-456a-ada9-ec394ddab3ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cf19b91e-c408-456a-ada9-ec394ddab3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_58a4f465-0eaf-4dd7-8568-a7373d04db52" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentFiscalYearFocus_58a4f465-0eaf-4dd7-8568-a7373d04db52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ebed184a-8594-4439-b400-69ceb337c18b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_CurrentFiscalYearEndDate_ebed184a-8594-4439-b400-69ceb337c18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4f54c757-f617-46f0-ba43-bdef8d207940" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityFileNumber_4f54c757-f617-46f0-ba43-bdef8d207940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_be33b818-acfa-41c7-81f3-de94151054c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityRegistrantName_be33b818-acfa-41c7-81f3-de94151054c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d1c80ec3-95ff-4e9e-b555-78af8eb2cce1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityCentralIndexKey_d1c80ec3-95ff-4e9e-b555-78af8eb2cce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber_94eb1919-2d1c-4d23-ba38-516112748f92" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityPrimarySicNumber_94eb1919-2d1c-4d23-ba38-516112748f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a19db963-4373-4cba-afd1-959977c5514b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityTaxIdentificationNumber_a19db963-4373-4cba-afd1-959977c5514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5128f85d-61f2-40a6-853c-122310f8d951" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5128f85d-61f2-40a6-853c-122310f8d951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2ef2f5d0-65e7-4306-83d1-1f7b9367f81c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressAddressLine1_2ef2f5d0-65e7-4306-83d1-1f7b9367f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0ddbf551-9cb3-47b3-82ee-1c1b75812fff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressAddressLine2_0ddbf551-9cb3-47b3-82ee-1c1b75812fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3_405cbd4e-4ed7-4453-a126-bce85ea2c2f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressAddressLine3_405cbd4e-4ed7-4453-a126-bce85ea2c2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_44372a82-3ae3-43f8-a7d0-852852500b74" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressCityOrTown_44372a82-3ae3-43f8-a7d0-852852500b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7009edc1-ec7e-4140-9e9d-c45f36327de8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressStateOrProvince_7009edc1-ec7e-4140-9e9d-c45f36327de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_643e3e8a-4a88-4dca-8f03-7ea0280dbedb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressCountry_643e3e8a-4a88-4dca-8f03-7ea0280dbedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_784acdf1-1d58-4f8d-b6e3-18f27180fe3c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityAddressPostalZipCode_784acdf1-1d58-4f8d-b6e3-18f27180fe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_96e0e9a8-d290-4701-87e5-4ed73bfffb3e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_CountryRegion_96e0e9a8-d290-4701-87e5-4ed73bfffb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ea1fe7c0-763b-432e-affa-3fdc4f95c29c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_CityAreaCode_ea1fe7c0-763b-432e-affa-3fdc4f95c29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a016e0af-c076-4520-a2d7-b57c764d332b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_LocalPhoneNumber_a016e0af-c076-4520-a2d7-b57c764d332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Extension_0ed2fc37-372b-41bc-bb80-0365b1d3c7c1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_Extension_0ed2fc37-372b-41bc-bb80-0365b1d3c7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7bcf4545-ba49-496d-b9ba-d0f426384bff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_WrittenCommunications_7bcf4545-ba49-496d-b9ba-d0f426384bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5d8c837a-1ae9-4d06-a56b-79e2c85532b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_SolicitingMaterial_5d8c837a-1ae9-4d06-a56b-79e2c85532b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1af0f41c-4616-4f27-b27b-050cebb7cc77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_PreCommencementTenderOffer_1af0f41c-4616-4f27-b27b-050cebb7cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_bcb7d589-e1c2-44f6-bd39-bf16918d6692" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_bcb7d589-e1c2-44f6-bd39-bf16918d6692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_27358617-c26d-4973-90a6-cbe024f55378" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_Security12bTitle_27358617-c26d-4973-90a6-cbe024f55378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_ef60e8dc-a850-41ee-8124-eccaf67e4b95" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_NoTradingSymbolFlag_ef60e8dc-a850-41ee-8124-eccaf67e4b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5e5a23e0-ed21-47fc-b2bd-c45892356dd8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_TradingSymbol_5e5a23e0-ed21-47fc-b2bd-c45892356dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_40ca9e4c-655b-4cdc-aa79-081241a0a87f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_SecurityExchangeName_40ca9e4c-655b-4cdc-aa79-081241a0a87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12gTitle_35a9426f-1447-4b54-9ab0-a21fdb160fe8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_Security12gTitle_35a9426f-1447-4b54-9ab0-a21fdb160fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityReportingObligation_39b98383-5f54-4deb-94d0-595b45d70e56" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_SecurityReportingObligation_39b98383-5f54-4deb-94d0-595b45d70e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm_0e4ac476-50f5-462d-b9d6-4203e11b512c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_AnnualInformationForm_0e4ac476-50f5-462d-b9d6-4203e11b512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements_93648074-abec-418f-8bf8-7502bad01c60" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_AuditedAnnualFinancialStatements_93648074-abec-418f-8bf8-7502bad01c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1efa8b52-7e0d-4417-8523-fd713c569971" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1efa8b52-7e0d-4417-8523-fd713c569971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ab3e3dde-8550-4d98-a410-58f8c150f38a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityVoluntaryFilers_ab3e3dde-8550-4d98-a410-58f8c150f38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3c140c72-0129-4be5-af9f-20f44bdb587e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityCurrentReportingStatus_3c140c72-0129-4be5-af9f-20f44bdb587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_84711c0e-0d84-467f-9790-510451064c59" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityInteractiveDataCurrent_84711c0e-0d84-467f-9790-510451064c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e7dce910-7b7d-40dc-ba74-d880068a5b3d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityFilerCategory_e7dce910-7b7d-40dc-ba74-d880068a5b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1893e75d-6c4d-40a0-829e-c6f7d0af5984" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntitySmallBusiness_1893e75d-6c4d-40a0-829e-c6f7d0af5984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_03973759-a540-4c90-ba3a-7a74a6d778ad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityEmergingGrowthCompany_03973759-a540-4c90-ba3a-7a74a6d778ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_86f3c98a-f188-4b66-9dbf-7db15299248b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityExTransitionPeriod_86f3c98a-f188-4b66-9dbf-7db15299248b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_44a0c535-702b-4f42-b46b-f43299154ea8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentAccountingStandard_44a0c535-702b-4f42-b46b-f43299154ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherReportingStandardItemNumber_3cf9b0b1-0e93-406a-91aa-a34b27832109" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_OtherReportingStandardItemNumber_3cf9b0b1-0e93-406a-91aa-a34b27832109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3672ccae-a3f7-4d68-92c7-019f016f1783" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityShellCompany_3672ccae-a3f7-4d68-92c7-019f016f1783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_68dca350-642b-4817-a22d-4f10907a1268" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityPublicFloat_68dca350-642b-4817-a22d-4f10907a1268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityBankruptcyProceedingsReportingCurrent_522610c7-b8ea-4b60-8b70-0adab6c15f41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityBankruptcyProceedingsReportingCurrent_522610c7-b8ea-4b60-8b70-0adab6c15f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f16d6f22-796e-4e6c-86d0-5f2c22b90a75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f16d6f22-796e-4e6c-86d0-5f2c22b90a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_05b52bf5-1e73-4102-9254-1e98ad561d07" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aee0c5fe-af79-4c82-b92a-840c65f88948" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_05b52bf5-1e73-4102-9254-1e98ad561d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !=T    $" 8   ![HI:_    "7!(67,  $SE
M  !,Y0%USO"5    04E$051XVNW8,0T   @#P?HW#0D68&"X3\Y QR9) 0
M    :Y,A      # Z0X      +].=TF2)$F2)$F2=% #$WZ#;*/0WX8
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@   ^D    %" 8    Y4ZT;    "7!(67,  $SE
M  !,Y0%USO"5    /$E$051XVNW700T   @#L?DW#0DFV*.7U,!^2Y(!
MWEV&     "<=    <-(!  "@\*1+DB1)DJ2"%O .D4)"RJ:I     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>serina.jpg
<TEXT>
begin 644 serina.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #? O@# 2(  A$! Q$!_\0
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M6$T:]V2\^II"#LZ,BQXRM6M=2%RHPG!!K9BF75?"N^4@R*I.!5*\F_X2+0$
M8>9&<D'K@5G^&9_W-W"QXV8Q7'+$PP^+JRIOW)Q_%CLY05]TRQX#NDM[J5&.
M&8\53O#GQ(W^^:K:6OV?Q!"!P%>K,WS:^?=B:X:.)_V6A0E_R[E<U<??;[E[
MQI> ^1;_ ,10&KFEWRZ;X;+NNUFRHXK!\23"XU2W('"@#^57O$ETJZ;#;*,,
M,&M?[0Y:F(Q$7J]B?9W48E;PK;G4-5,K\E3DUH^-O$'G2?8X<@+\KTS1=FBZ
M.UVY"R2K@5FZ18R:YJOG.,INR];1K5883ZG2^.MJR>5<_.]D=+X+T1=/A^VS
MX!ZJ?:L[Q?XF;4)?LUN?W6<''7-2^*/$*V]I]@MSP!@XJOX2\-/>2_:[D8B7
M^%NOUKV:U2<J<,ERW9ZS?GU,U%)NM4^1H^#?"Q7%W<+R>F:Z36O$UOHMN<,"
M^. .:R_$7BJ'2[?R;<[GQCY>U<39V=YXBO=S[FW'EL<5[?\ :U'((1RW*H\U
M1[M:F/LW6?M*NB/5/#NLKK%FDN<L1DBM?-8GAW0XM%MPJ_?8<FMO@U^UY/+$
M2P</K7Q]3RJO+SOEV"EI*6O=,0HHHH *2EHH @NIA;V\LS=$4L?PKXN^-WC)
M_$_BZXB$C?9H6RJYQZU]DZW_ ,@F]_ZXM_*O@CQSQXAU''7M^=85#6F=9\+?
MA3=>/M0#.A2P0C>?NY'L:^F_#?P7\/\ AUX)8H"\L8Q^\PPJK\ H[5?AMI#1
M;3<&$>9CK^->D54(JQ,I-LS?^$;TS_GRM_\ OTO^%'_"-Z9_SXV__?I?\*TZ
M*TLB#D]>^&>A^(%(N+54_P"N:A:\)^*7[/;:/#+J&BJS1("S(3N8_05]0TWR
MPZX8 CT(J903*4FC\\+>XN=(U 2QEX;B%L$<@BOM/X/^-T\9>&8G9P980(SZ
M\"O!_C1\)-2L?$SW>F6DEQ%=%I'$29P:V_V<=)U[P_XD^R7=E<6]DZLY:1<#
M-8QO&5C25FKGTY1245TF)R?Q*\81^#?#-W>;U6X5-T8/<_2OB3Q%X@N_$NJ3
M7MS(TAD8LJY/?VKUO]I;Q2^HZU!IZ2[D@8JR@_6N'^$W@\^,/%MK 4W6P.'/
M8=*Y9-R=D;QLE<W?A?\  ^_\<1B\ND,%FK8*ME6/N*^A_#OP5\.^'XXQ% SL
MN"?,^;FNUTRPCTRRAMHU55C0+P/05;K6,$C-R;,W_A'--_Y\K?\ []+_ (4?
M\(WIG_/C;_\ ?I?\*TJ-U:61!R.N?#+0M?\ ]?:JA Q^[4+7A?Q2_9Z.AVLF
MH:*K,@.2C$L?RKZB_BILL:S*4=0RL,$&IE%,I2:/SOAFN=+O$D0R6]Q"^=O*
M\@U]@? WXC-XRT-(+IU-[$N7QQ7C7[17@'^P?$#:M:Q[;24*FT#^+N:YCX,>
M*)_#/C*W6.3;'>.L;_2N>-XNQJ_>1]O+Z4M-CD610R'<IZ$4ZNLP.5^)7_(J
M7?\ NG^1KX07_CXN/^NK?S-?=_Q*_P"15N_]T_R-?!_W9KD]O-?^9KEJ[F]/
M8ZK5/'%[J7A73= @W[+=R0L8.6R.G'6O0OAG^SS+XBM[>^U<-':R#=L!*OBL
MW]G_ ,!KXF\0&]N$W16^)$R.,U]>1QK$H55"J.@ JH1YM6*4K:(X?1_@WX=T
M4Q^3;EB@P-^#74+X:TQ5 %C;X'_3)?\ "M.@&MN5&5S/B\/Z?"X=+.!&'=8U
M!_E6AM HI:H0G3-?!GQ*_P"1ZU;_ *[M7WFW2O@SXE?\CUJW_7=JPJ[&M/<]
MO_95_P"0/<?]=C_6OH6OGK]E7_D#W'_78_UKZ%JX?"3+<*Y/XH_\B/JO_7*N
MLKD_BC_R(^J_]<JM[$H^%;Y=UY,/^F@->D?%/QU+XAATC2;%W>%;6-66,G[P
M ':O.KK_ (_;C_>KV#]G?X<QZ]JPU6]3S+>,E=I]>U<<;WLCH=MV6/AA^SS)
MXALX[[6 4A8\*#M:O;M(^#/AW1_*\J L8^1OP:[F&%(8E1%"JHP *?S75&*1
M@Y-F6OAG35&!96__ 'Z7_"JVI>"=(U2W,4MG$JG^Y& ?Y5NT55D*[/)/%7[/
M.@ZQ:NUNCQW&/E^; KYJ\=?#_4? VHO!=1EH<_+(HR/SK[OR:X[XH^#[;Q9X
M9N(IHU9HE:13CG(%9R@K%QDUH?(_PQ\93^#?$UN\<C"&=PC@G@"OM[1]2CU;
M3H;N)@T<@R"#7Y\:E9R:;<36\G#QDU]A_L^ZQ)J'@>RA?.(8P!FLZ<GL5-=3
MU&DS2TE=)B0WETMG;2S.<+&I8_A7QQ\:OB3=>*_$,UI#,1I\+94*<9^M?3GQ
M5U*ZT_PK<?9())Y9E:/;&,GD5\:V_@?7KJ[C273;G]X^"Q2L*C>QK!+=FM\-
M_AC?_$*]=85"6T1&]FXR/8U]+>%?@+H&@6Z;XFDFZL6.X9K:^$_A.'PQX4LX
MQ#Y=PR?O,CFNTZTXP26HI29F1^&M,2-4%E!A1@9B7_"G_P#".:;_ ,^-O_WZ
M7_"M*BM;(@YG6/A[HNMQJD]I&H!S^[0"O'OB)^SA:BUN;[1@RS ;MK-D?E7T
M-R*0_,#D9%2XICYFC\[[^QN=+O)+>=7@GB;!(RN?I7TY^SA\0GU;33I=[(6N
M5;Y#_LBN1_:<\'K8ZE:ZG;0[8=A,K =R:X+X,ZQ)I?C2)EE$,9B8[FZ5SKW)
M&S]Y'W#1245UG.,F7<I'2O,/$GA:]749[J+=(&;( %>H-][K3'C63@\U\EG^
M0T\\H^SGHSHHUG1=T>.V^L:GHK8<NB_W:Z/3OB/P$FB/^\378W6@V5T#YD*,
M?<5RVH?#N.1F:*0KW"@5^65,AXBR+WL%6YHKH>DJU"M\:.BT_P 36=]C;,NX
M]LUJ'9,N,Y%>27'A?5-+):%& '\0IEGXJO\ 37 D=I,=F-=.'XXQ.%_<YIAW
MZV)E@XRUIR/0M8\(VFI*Q"*LAZ-7GVJ>%KW2)S)$&8+T8=JZG2_B%#+M%SMB
M/UKHX=4L-5CPK+(#3Q>!R#B)>UPE54ZOJ*$Z]#22NC@=#\=3V'[JX#2X.,YZ
M5UZW-CXHM=A*L>N/2L_7?!%OJ#&2V_=''W5'6N+NK/4?#DW#/$N>H[UX$L5F
MN0IX;'0=>@^J70VY:5;WH.S+WB'PO-H\PGM_F0'/RCI5KP_XJW*;2]/F1OQE
MCTJ72?&45POD7ZJ5Z;F[U6U[0(IE^UZ?\T9YPHX%>&Y4\,WCLIG9=8=3?XER
M55\RKXDT,V,GVJV^:!OFW+T%36>H?V]8FSF.)%&58^U5M)UQH<VE]\\+'!W_
M ,-0:A9G3;@7-LY:(\[AQCVKY[$8RG3;K45RQ?Q1\^YM&+?NRW[B:3.VGWDD
M4GRAAMP:8[?V7J^U6Q'GGWJ#4+P7D@E V.,=*;;V=SJDA\M#*]?*O$UJ]J&&
MBY._0Z>51]Z6A-]I3^W#..(R^<U)/?*NH+.IW*,UHV?@6]GV>8C(#U]JT?\
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MZYFDP/B7XLWT=]X\U66)@R^;D8KV/]E7P_LLM0O7//F@C\J\!\6#=XJU3/\
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MC)Q=F4US*Z/M9:SO$7.BWN.?W9K0A8R0HQZLH-,NH5FMWC895A@UT]# _/\
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MBXCL9R<&*1N:UC-,S<&CU&BN?'C[P\?^8K;_ )G_  I?^$]\/_\ 05M_S/\
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M "H ^%_BC_R/.H?Y[FO8?V4_O:K_ ,!_I7CWQ2_Y'K4/\]S7L/[*?WM5_P"
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MU:4W#9W>1*O ]J]WAL;>WYBB5/\ =%3]:I4TA.=SR?X[>'I[CP#/8Z7:[P%
M6).G>OEM/ /B95 _LIZ^^9K>.X39*BNOHU5_['LO^?:/_OFB5.X1EREM?NCZ
M44M%:F9S7BCQ3'H>5(/F'@<<9QFN.E^(%Y(C !<_2NW\0>&8=<E4RCH<]?;%
M4X? &F1X)C8G_>K\@SK+^(L;BY+"34:=W]U]#TZ,\/"/O+4X:Y\5:G=(%V,
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M:],';<T;=6)KO=%\%VVGJK2#S'Z_,*Z&&TAM5 1%7Z#%8WB#Q1!I<+#=F3'
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MZ;G_ (_;?_OZO^-"BNX^9GR%_P )!XQ^$>KQK?-))"&'R2.2NW/7I7U/\/\
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M2Q7*K(P$I:**H HHHH **** "BBB@ K+\1>'[7Q)IDUG=1JZR*5&[MFM2DH
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-38519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Serina Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1436829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Genome Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Huntsville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-9630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (&#CEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( (&#CEJ#YOX4[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M)%;:'6!%@CQF\:+ZH<,U:*/5Z]!KA*97T/3.H7D2*^D>.,C7(X\K\X/KS*
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MQCV&5G8*BIO[>[2I,A:,YB^9GGXR<,56I^=W,;:R6U#<ZO--',&8?1H%%_C
M.MV/&$K9*BCN\??*-=+I6B58YZH1:;&KQG6WY6-$96.@N)\_:VFM2" U<9PE
M!_,UE52X4-U Q,J>P' #GZE(!M+*9$4>H,"UY%'E"(NKU/*4'8#A'CW5HA%
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ @8..6I>*NQS     $P(   L
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MU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ @8..6B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ @8..6D;'34B5    S0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "!@XY:@^;^%.\    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( (&#CEJJQ"(6,P$  "("   /
M  "  9\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "!@XY:)!Z;HJT
M  #X 0  &@              @ '_$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "!@XY:99!YDAD!  #/ P  $P
M@ 'D$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   N%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ser-20250408.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serinatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ser-20250408.htm">ser-20250408.htm</File>
    <File>ser-20250408.xsd</File>
    <File>ser-20250408_lab.xml</File>
    <File>ser-20250408_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ser-20250408.htm": {
   "nsprefix": "SER",
   "nsuri": "http://serinatherapeutics.com/20250408",
   "dts": {
    "inline": {
     "local": [
      "ser-20250408.htm"
     ]
    },
    "schema": {
     "local": [
      "ser-20250408.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ser-20250408_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ser-20250408_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://serinatherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ser-20250408.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ser-20250408.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Information Form",
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audited Annual Financial Statements",
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period Start Date",
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Event Date",
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference [Text Block]",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Three",
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current",
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Primary SIC Number",
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension",
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Reporting Standard Item Number",
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(g) Security",
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Reporting Obligation",
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001708599-25-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001708599-25-000042-xbrl.zip
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MX%E)40Y;\HC=<3\5[$]@1K7;';:$-](;&J[)G<MY-&A?X1"2FPB,BQC/$9_
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MD#XII<1RJ>1+V^+64E;?ZWQNNVJG%VQSGHY;_2V/TROH;C<1J.LUZ%?PY6Z
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M@B!8JRY5QC8:'JAH5#?.1<8TD,3;<V ?\(YJV*%W5?%RHJTP3^5-F!09>L1
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M8]+D3&=WTER2F%QF!/ZBS1$\>Z3^4,BX.>UN^KWRY2E.\R4VBJ5<"91RY.?
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M>6+,?RH?-V$RUA>K+NOU[9SLKB=L+@_JWO4NQFT#@+WN-5XZ$Q6>$UF;MX1
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MXZS6"QPQ\S;P1@?<[ROF[H O?K/12N6$,3)"U'H;F2FK$.%<6?!EJ20NK/9
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M"O@K+SW*CHC#"&5&X68>%\[&J0&!:YR-U$0FF1EWW1<(&:"_SVF03+]+F^4
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M7WX]=0=BA.=KHS3GN-X-]^5Y=YD["9XMX8FBE/HX,ZWKQC 6(^B<$:: ^V+
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M)%"%^X*1=2'52A=2(:]O@N<YL<&[$+U(SQ-+&_C$!^G]#DL+J4EN.$E4#?#
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MC$:MLK5.VOM^EX:/V/)M?XP0GY[UGX[PPM@O7)8?BBIRJ\@WYG;J/*[=MW^
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M&RJ]&]X/_:>VB] 82AVDR A$@X S28D#ETB4*@LMN$FP1,7K8>O3Z*B^ +J
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MS/%9\O0QQ/79V#;A?JK^W ,]$J'!;L&*T8.?$NOH"0>V)%)8'H0N%!2R3+Z
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MWWC]_#S^I>MS_@O;?P-02P$"% ,4    " "!@XY:P#>Z+.\H  !^10$ '@
M            @ $     97@Q,#%?<&EP97-E8W5R:71I97-P=7)C:&$N:'1M
M4$L! A0#%     @ @8..6N,!YXS--P  #[$! !X              ( !*RD
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M+3(P,C4P-# X7W!R92YX;6Q02P$"% ,4    " "!@XY:EF%U3[ ,  !H*P
M'@              @ 'MGP  <V5R+3(P,C4P-# X>&5X.3DQ<')O;G!I<&4N
9:'1M4$L%!@     '  < Y $  -FL      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>ser-20250408_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ser-20250408.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708599</identifier>
        </entity>
        <period>
            <startDate>2025-04-08</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001708599</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-24">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-04-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Serina Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-38519</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">82-1436829</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">601 Genome Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 2001</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Huntsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">35806</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">(256)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">327-9630</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">SE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
